Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
Brennan
F M
FM
Kennedy Institute of Rheumatology, Hammersmith, London, UK.
Cope
A P
AP
Katsikis
P
P
Gibbons
D L
DL
Maini
R N
RN
Feldmann
M
M
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000209:etiology / Q000628:therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D006801:Humans; D007165:Immunosuppression Therapy; D016753:Interleukin-10 / Q000502:physiology; D015847:Interleukin-4 / Q000502:physiology; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors; D016212:Transforming Growth Factor beta / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology
D016207:Cytokines; D018124:Receptors, Tumor Necrosis Factor; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D015847:Interleukin-4